Výsledky vyhledávání

ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

Autor: Vadim V. Ptushkin, K D Kaplanov, Valerii A. Ionin, Larisa P. Mendeleeva, Tatiana E. Bialik, Loic Ysebaert, Evgenii A. Nikitin, EA Stadnik, Olga Samoilova, Vladimir I. Vorob'ev

Publikováno v: Современная онкология, Vol 23, Iss 3, Pp 404-406 (2021)

Over the past decades, there has been a significant expansion of the treatment options for patients with chronic lymphocytic leukemia (CLL) due to Brutons tyrosine kinase (BTK) inhibitors, which changed approaches in CLL therapy. Ibrutinib was the fi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a936f037946e50f70cf280849c6ac2
https://modernonco.orscience.ru/1815-1434/article/viewFile/88010/pdf

Zobrazit plný text záznamu

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Autor: Olga Samoilova, Valentina Molostvova, Vadim V. Ptushkin, T. I. Pospelova, Evgeniy A. Nikitin, K D Kaplanov, Irina V. Poddubnaya, EA Stadnik, Al'-Radi Ls, Tat'yana Evgen'evna Byalik, Gayane Tumyan

Publikováno v: Современная онкология, Vol 22, Iss 1, Pp 31-33 (2020)

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d877247d308e82482df670eaa98d22b
https://doi.org/10.26442/18151434.2020.1.200090

Zobrazit plný text záznamu

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

Autor: T. I. Pospelova, Tatyana E. Bialik, EA Stadnik, Natalya N. Glonina, Nadezhda V. Medvedeva, Irina V. Poddubnaya, Evgeniy Aleksandrovich Nikitin, V A Lapin, K D Kaplanov, Olga B. Kalashnikova, Natalya B. Mikhailova, Moiseeva Tn

Publikováno v: Современная онкология, Vol 21, Iss 4, Pp 45-47 (2020)

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy sche

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059f43969dcfd4d98fb75d9105dd68c2
https://doi.org/10.26442/18151434.2019.4.190725

Zobrazit plný text záznamu

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia

Autor: TS Nikulina, Pavel Butylin, EA Stadnik, YuV Virts, TO Andreeva, VV Strugov, AYu Zaritskey, AG Rumyantsev, YuV Mirolyubova

Publikováno v: Kliničeskaâ onkogematologiâ, Vol 11, Iss 2, Pp 167-174 (2018)

Background. In patients with chronic lymphocytic leukemia (CLL) the eradication of minimal residual disease (MRD) is a prognostic factor of overall survival (OS) and progressionfree survival (PFS). IGHV mutational status has also independent prognost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aba4fc981644011309b83c9d2258865
https://doi.org/10.21320/2500-2139-2018-11-2-167-174

Zobrazit plný text záznamu

Role of Superficial CD200 Marker in Differential Diagnosis of Malignant B-Cell Lymphoproliferative Diseases

Autor: TO Andreeva, VV Strugov, Roman Grozov, EA Stadnik, AYu Zaritskey, TS Nikulina, YuV Mirolyubova, YuV Virts

Publikováno v: Kliničeskaâ onkogematologiâ, Vol 10, Iss 2, Pp 169-175 (2017)

Background & Aims. Flow cytometry is successfully used for diagnosis of malignant lymphoproliferative disorders. However, there are atypical cases that are difficult to interpret; thus, new markers relevant for the differential diagnosis are to be se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e3cbc681f9181df1676b474e43a5a3
https://doi.org/10.21320/2500-2139-2017-10-2-169-175

Zobrazit plný text záznamu

Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

Autor: EA Stadnik, YuV Virts, TO Silina, AYu Zaritskii, VV Strugov

Publikováno v: Kliničeskaâ onkogematologiâ, Vol 9, Iss 2, Pp 162-175 (2016)

Background & Aims. New schemes of the antitumor therapy of CLL resulted in improvement of survival of relatively young patients. However, the therapy outcomes of elderly patients are still unsatisfactory. Erroneous overestimation of expected toxicity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91d491113ea925bfbfc9b72e180b254
https://doi.org/10.21320/2500-2139-2016-9-2-162-175

Zobrazit plný text záznamu

Prospective analysis of efficacy and safety of BR regime in the first-line treatment of chronic lymphocytic leukemia

Autor: VV Strugov, EA Stadnik, Yu V Mirolyubova, Pavel Butylin, A Yu Zaritskiy, TO Andreeva, Yu V Virts

Publikováno v: Modern Oncology. 18:33-35

This trial has evaluated a systematic prospective analysis of the efficacy and safety of BR in CLL patients in the routine clinical practice. It included 179 patients with verified CLL diagnosis and the presence of the indications for initiation of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd87d23976b5b802a3210343214db51d
https://doi.org/10.26442/1815-1434_2016.5.33-35

Zobrazit plný text záznamu

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

Autor: Tatyana Andreeva, EA Stadnik, Andrey Zaritskey, Yulia Virts, Vladimir Strugov

Publikováno v: Annals of hematology. 97(11)

CLL is an aging-associated neoplasm with median age at diagnosis > 65 years. Little is known about safety and efficacy of FC/FCR regimens in elderly CLL patients with multiple comorbidities. We retrospectively revised medical records of 90 patients t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ff733cf313b8edd4ba04ebd28aa59d
https://pubmed.ncbi.nlm.nih.gov/29946909

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání